Krystal BiotechFRA:4KB +2.29%58 Gross Margin % is 94.57% as of Mar. 2026, which is 1% above its 10-year median of 93.90. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 737 Biotechnology companies, Krystal Biotech ranks better than 91.59% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Krystal Biotech had a gross margin of 94.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Krystal Biotech Gross Margin % Related Terms
Krystal Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Gross Margin % Comparison
For the Biotechnology subindustry, Krystal Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Krystal Biotech (FRA:4KB) has a Gross Margin % of 94.57% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Krystal Biotech and its competitors. This is near median its historical median of 93.90. Over the past decade, Krystal Biotech's Gross Margin % has ranged from 93.09 to 94.17. According to the industry distribution chart, Krystal Biotech ranks #62 out of 737 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Krystal Biotech's Gross Margin % too high?
Krystal Biotech's current Gross Margin % of 94.57% is near median its 10-year median of 93.90. Over the past 10 years, this metric has ranged from a low of 93.09 to a high of 94.17. The Biotechnology industry median Gross Margin % is 60.92. Krystal Biotech's value of 94.57% is 55.2% above this industry median. Based on the distribution chart, Krystal Biotech ranks #62 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Gross Margin % compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #62 out of 737 companies for Gross Margin %. This places Krystal Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Krystal Biotech's value of 94.57% is 55.2% above this benchmark. Historically, Krystal Biotech's own Gross Margin % has ranged from 93.09 to 94.17 over the past decade. While the company's 10-year median is 93.90 vs. the industry median of 60.92, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Gross Margin % of 94.57% is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Gross Margin % is 94.57%, which is near median its own 10-year median of 93.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current Gross Margin % is 94.57%, which is near median its 10-year median of 93.90 and 55.2% above the Biotechnology industry median of 60.92. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Gross Margin % is 94.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Gross Margin %: 94.57% (near median its 10-year median of 93.90)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
Industry Position: 55.2% above the Biotechnology median (#62 of 737)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
